|
PSCI-18-131 |
Micro/nano technology for extracellular vesicle isolation and towards non-invasive pancreatic cancer diagnosis |
|
PSCI-18-143 |
Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR |
|
PSCI-19-021 |
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS) |
|
PSCI-19-049 |
AGCT1532, Randomized Phase 3 Trial of Accelerated vs Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastic Germ Cell Tumors |
|
PSCI-20-009 |
Effect of oral black raspberry administration on oral cell DNA adducts in smokers |
|
PSCI-20-013 |
Difference in care and trends in outcomes of adolescent and young adult AML patients treated in pediatric and adult centers |
|
PSCI-20-020 |
A Phase 1/2, Open-label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects with Advanced or Metastatic Malignancies Harboring ALK, ROS1, or NTRK1-3 Alterations (CARE) |
|
PSCI-20-023 |
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy |
|
PSCI-20-025 |
A Multi-Institutional Retrospective Study of Patient Characteristics, Treatment Patterns and Outcomes in Older Patients with Primary Central Nervous System Lymphoma |
|
PSCI-20-035 |
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma |
